IMRiS试验:对极端软组织肉瘤强度调节放射治疗的第二阶段研究
Beatrice Seddon1, Franel Le Grange1, Rita Simões2
1London Sarcoma Service, Department of Oncology, University College Hospital, London, United Kingdom.
概括
对四肢软组织肉瘤 (STS) 的强度调节放射治疗 (IMRT) 显示了10.8%的显著皮下纤维化率. 这种先进的辐射技术为患有四肢STS的患者提供了好处,具有可接受的毒性.
科学领域:
- 辐射瘤学 辐射瘤学
- 手术瘤学手术瘤学
- 医学物理 医学物理
背景情况:
- 主要软组织肉瘤 (STS) 是罕见的,通常会影响四肢.
- 节约肢体的手术与放射治疗 (RT) 结合,是高风险病例的标准.
- 在RT后的晚期正常组织毒性和肢体功能需要彻底调查.
研究的目的:
- 在极端STS中进行强度调节放射治疗 (IMRT) 后,前性评估晚期正常组织毒性和四肢功能.
- 在IMRT后24个月确定≥2级晚期软组织纤维化率.
- 为了比较术前和术后RT队列之间的结果.
主要方法:
- 对接受IMRT的肢体STS患者 (年龄≥16岁) 的前性研究.
- 两个队列:手术前的IMRT (50 Gy) 或术后的IMRT (60/66 Gy).
- 主要终点:使用放射治疗瘤学小组 (RTOG) 标准,在24个月后≥2级晚期皮下纤维化.
主要成果:
- 159名患者接受IMRT;中位数随访时间为35.2个月.
- 10.8% (95% CI,5.7%-18.1%) 在24个月经历了2级以上的皮下纤维化.
- 观察到较低的皮肤,骨和关节毒性率;手术前的RT有更多的伤口并发症 (29.2%对3.8%).
结论:
- 10.8%的≥2级皮下纤维化率与其他IMRT试验一致,低于历史的3D-CRT率.
- 关于晚期毒性,IMRT证明对四肢STS患者有好处.
- 这项研究支持IMRT在管理四肢STS的使用.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


